Table 1.

Study endpoints and statistical tests by which they were analyzed ^a .

Endpoint	Statistical Method	Location	Unit of Analysis
Within-group differences in body weight, plasma glucose, and log UAER from baseline to follow-up a	Paired t-test with multiplicity correction (Benjamini-Hochberg)	Table 2	Per animal
Between-group differences in percentage delta change in body weight, plasma glucose, and log UAER from baseline to follow-up, and in serum cholesterol and triglycerides at study close	Unpaired t-test with multiplicity correction (Benjamini-Hochberg)	Table 2	Per animal
Between-group differences in qRT-PCR data (kidney, liver, and epididymal fat)	Wilcoxon rank-sum test with multiplicity correction (Benjamini-Hochberg)	Figure 2	Per animal
		Supplemental Figure 4
Between-group differences in histological (glomerular volume) and ultrastructural (podocyte foot process frequency, podocyte foot process diameter, glomerular basement membrane thickness, and mitochondrial roundness) parameters	Wilcoxon rank-sum test with multiplicity correction (Benjamini-Hochberg)	Figure 8B	Per individual structural measurement
		Figure 9B–D
		Figure 10B–D
Correlations between renal cortical transcripts and urinary metabolites with morphometric parameters of glomerular and proximal tubular injury	Pearson correlations	Figure 8C	Per animal
		Figure 9E
		Figure 10E
Differences in mitochondrial morphology between the pars convoluta and pars recta proximal tubular sections	Wilcoxon rank-sum test	Supplemental Figure 5	Per individual structural measurement
Differences in mitochondrial roundness between RYGB and RYGB-FMRR animals matched for improvements in metabolic control and albuminuria	Wilcoxon rank-sum test	Figure 11	Per individual structural measurement

^aqRT-PCR, quantitative reverse-transcription polymerase chain reaction; RYGB, Roux-en-Y gastric bypass; RYGB-FMRR, Roux-en-Y gastric bypass plus fenofibrate, metformin, ramipril, and rosuvastatin; UAER, urinary albumin excretion rate.